Abstract
Medical leaders today call increasingly for patient-centered care, which is often contrasted with doctor-centered care and disease-centered care. One threat to patient-centered care which does not easily fit into these categories, however, is what one might label drug-centered care. Drug-centered “care” arises when pharmaceutical industry marketing exerts a deleterious influence over both the medical profession and the general public. This influence is easy to detect when it assumes blatant forms such as financial incentives to overprescribe but is harder to perceive when it takes the form of changing the way we think about disease and indeed about human life. Two case studies that illustrate this deleterious influence are antidepressant drugs and drugs for type 2 diabetes. The inverse benefit law explains why these forms of pharmaceutical marketing constitute a threat to the public’s health.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Angell, M. 2004. The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.
Applbaum, K. 2009. Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster. Culture, Medicine and Psychiatry 33: 185–215.
———. 2010. Shadow Science: Zyprexa, Eli Lilly, and the Globalization of Pharmaceutical Damage Control. BioSocieties 5: 236–255.
Avorn, J. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf.
Boussageon, R., T. Bejan-Angoulvant, M. Saadatian-Elahi, et al. 2011. Effect Of Intensive Glucose Lowering Treatment On All Cause Mortality, Cardiovascular Death, And Microvascular Events In Type 2 Diabetes: Meta-Analysis Of Randomised Controlled Trials. British Medical Journal 343: d4169.
Braun, S.R. 2013. Promoting “Low T”—A Medical Writer’s Perspective. Journal of American Medical Association Internal Medicine 173: 1458–1460.
Brody, H. 2007. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham: Rowman and Littlefield.
Brody, H., and D.W. Light. 2011. The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. American Journal of Public Health 101: 399–404.
Dolan P.L. 2013. Physician EHRs Emerge as Hot Advertising Venue for Drugs. American Medical News. http://www.amednews.com/article/20130121/business/130129987/4/. Accessed 12 Sep 2014.
Duggan, P.S., G. Geller, L.A. Cooper, and M.C. Beach. 2006. The Moral Nature of Patient-Centeredness: Is It “Just the Right Thing to Do”? Patient Education and Counseling 62: 271–276.
Farmer, A.J., R. Perera, A. Ward, et al. 2012. Meta-analysis of Individual Patient Data In Randomised Trials Of Self Monitoring Of Blood Glucose In Patients With Non-Insulin Treated Type 2 Diabetes. British Medical Journal 344: e486.
Friedman, R.A. 2012. Grief, Depression, and the DSM-V. The New England Journal of Medicine 366: 1855–1857.
Gagnon, M.A., and J. Lexchin. 2008. The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Medicine 5(1): e1.
Gerstein, H.C., S. Yusuf, J. Bosch, et al. 2006. Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomised Controlled Trial. Lancet 368: 1096–1105.
Gøtzsche, P.C. 2013. Deadly Medicines and Organized Crime: How Big Pharma Has Corrupted Healthcare. London: Radcliffe Medical Press.
Greene, J.A. 2008. Prescribing by Numbers: Drugs and the Definition of Disease. Baltimore: Johns Hopkins University Press.
Healy, D. 1997. The Antidepressant Era. Cambridge, MA: Harvard University Press.
———. 2003. Let Them Eat Prozac. Toronto: James Lorimer.
Kassirer, J.P. 2005. On the Take: How Medicine’s Complicity with Big Business Can Endanger Your Health. New York: Oxford University Press.
Kishore, P., S.H. Kim, and J.P. Crandall. 2012. Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do? Current Diabetes Reports 12: 255–264.
Leo, J., and J. Lacasse. 2008. The Media and The Chemical Imbalance Theory of Depression. Society 45: 35–45.
Light, D.H., ed. 2012. The Risks of Prescription Drugs. New York: Columbia University Press.
Montori, V.M., and M. Fernandez-Balsells. 2009. Glycemic Control in Type 2 Diabetes: Time for an Evidence-based About-face? Annals of Internal Medicine 150: 803–808.
Moynihan, R. 2010. Rosiglitazone, Marketing, and Medical Science. British Medical Journal 340: c1848.
Moynihan, R., and A. Cassels. 2006. Selling Sickness: How the World’s Biggest Pharmaceutical Companies are Turning Us All into Patients. New York: Nation.
Nissen, S.E., and K. Wolski. 2007. Effect of Rosiglitazone on the Risk Of Myocardial Infarction and Death from Cardiovascular Causes. The New England Journal of Medicine 356: 2457–2471.
Noble, P. 2013. FDA Eases Restriction to Avandia Access. Thomson Reuters/Life Science Connect. https://lsconnect.thomsonreuters.com/fda-eases-restrictions-avandia-access/. Accessed 13 Sept 2014.
Psaty, B.M., and D. Rennie. 2003. Stopping Drug Research to Save Money: A Broken Pact with Researchers and Patients. Journal of the American Medical Association 289: 2128–2131.
Reinhardt, U.E. 2001. Perspectives on the Pharmaceutical Industry. Health Affairs (Millwood) 20: 136–149.
Tanne, J.H. 2009. American Psychiatric Association Says No to Industry Funding for Symposiums. British Medical Journal 338: b1426.
Tiefer, L. 2006. Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance. PLoS Medicine 3(4): e178.
Torrey, E.F. 2002. The Going Rate on Shrinks: Big Pharma and the Buying of Psychiatry. The American Prospect 13: 15–16.
Turner, E.H., A.M. Matthews, E. Linardatos, et al. 2008. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. The New England Journal of Medicine 358: 252–260.
UK Prospective Diabetes Study Group. 2008. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Events in Type 2 Diabetes: UKPDS 38. British Medical Journal 317: 703–713.
Washington, A.E., and S.H. Lipstein. 2011. The Patient-Centered Outcomes Research Institute—Promoting Better Information, Decisions, and Health. The New England Journal of Medicine 365: e31.
Whitaker, R. 2010. Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. New York: Crown.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Brody, H. (2017). Patient-Centered Care or Drug-Centered Care: The Influence of Pharmaceutical Marketing on Medical Science and Public Health. In: Ho, D. (eds) Philosophical Issues in Pharmaceutics. Philosophy and Medicine, vol 122. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-0979-6_7
Download citation
DOI: https://doi.org/10.1007/978-94-024-0979-6_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-024-0977-2
Online ISBN: 978-94-024-0979-6
eBook Packages: Religion and PhilosophyPhilosophy and Religion (R0)